Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000636401 | SCV000757840 | likely pathogenic | Early infantile epileptic encephalopathy with suppression bursts | 2018-01-18 | criteria provided, single submitter | clinical testing | This variant identified in the SCN1A gene is located in the transmembrane spanning D4-S4 region of the resulting protein (PMID: 25348405, 18804930), but it is unclear how this variant impacts the function of this protein. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has been observed to occur de novo in an individual affected with focal epilepsy (Invitae database). This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with alanine at codon 1655 of the SCN1A protein (p.Gly1655Ala). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and alanine. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |